ID: ALA5274489

Max Phase: Preclinical

Molecular Formula: C22H18Cl2N4O2

Molecular Weight: 441.32

Representations

Canonical SMILES:  O=C(Nc1cnccc1-c1ccc(Cl)cc1)c1ccnc(NC(=O)[C@H]2C[C@H](Cl)C2)c1

Standard InChI:  InChI=1S/C22H18Cl2N4O2/c23-16-3-1-13(2-4-16)18-6-7-25-12-19(18)27-21(29)14-5-8-26-20(11-14)28-22(30)15-9-17(24)10-15/h1-8,11-12,15,17H,9-10H2,(H,27,29)(H,26,28,30)/t15-,17-

Standard InChI Key:  FDHSBDWKFQRDCY-JCNLHEQBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 441.32

Molecular Weight (Monoisotopic): 440.0807

AlogP: 5.01

#Rotatable Bonds: 5

Polar Surface Area: 83.98

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.94

CX Basic pKa: 4.62

CX LogP: 3.91

CX LogD: 3.90

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.55

Np Likeness Score: -1.22

References

1. Luo G, Chen L, Jacutin-Porte S, Han Y, Burton CR, Xiao H, Krause CM, Cao Y, Liu N, Kish K, Lewis HA, Macor JE, Dubowchik GM..  (2023)  Structure-activity relationship (SAR) studies on substituted N-(pyridin-3-yl)-2-amino-isonicotinamides as highly potent and selective glycogen synthase kinase-3 (GSK-3) inhibitors.,  81  [PMID:36669575] [10.1016/j.bmcl.2023.129143]

Source

Source(1):

• Scientific Literature